KemPharm (KMPH) Rating Increased to Sell at ValuEngine

KemPharm (NASDAQ:KMPH) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday, March 9th.

A number of other equities analysts have also commented on the company. Oppenheimer set a $13.00 price objective on KemPharm and gave the stock a “buy” rating in a research note on Sunday, February 25th. Canaccord Genuity set a $11.00 price objective on KemPharm and gave the company a “buy” rating in a report on Friday, February 23rd. Royal Bank of Canada set a $9.00 price objective on KemPharm and gave the company a “buy” rating in a report on Tuesday, January 16th. Finally, Zacks Investment Research downgraded KemPharm from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $9.95.

NASDAQ KMPH traded down $1.10 during trading on Friday, hitting $6.80. The company’s stock had a trading volume of 246,708 shares, compared to its average volume of 181,653. The company has a market cap of $115.79, a P/E ratio of -2.30 and a beta of -0.36. The company has a quick ratio of 7.56, a current ratio of 7.56 and a debt-to-equity ratio of -1.92. KemPharm has a 52 week low of $2.45 and a 52 week high of $8.40.

KemPharm (NASDAQ:KMPH) last announced its quarterly earnings results on Thursday, March 29th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.04). sell-side analysts expect that KemPharm will post -2.23 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of KMPH. Victory Capital Management Inc. boosted its position in KemPharm by 26.7% during the fourth quarter. Victory Capital Management Inc. now owns 162,077 shares of the specialty pharmaceutical company’s stock valued at $656,000 after purchasing an additional 34,114 shares during the last quarter. C WorldWide Group Holding A S boosted its position in KemPharm by 14.1% during the third quarter. C WorldWide Group Holding A S now owns 435,528 shares of the specialty pharmaceutical company’s stock valued at $1,611,000 after purchasing an additional 53,829 shares during the last quarter. Finally, Alyeska Investment Group L.P. boosted its position in KemPharm by 1.8% during the third quarter. Alyeska Investment Group L.P. now owns 992,338 shares of the specialty pharmaceutical company’s stock valued at $3,672,000 after purchasing an additional 17,721 shares during the last quarter. 36.56% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Enterprise Leader and is the sole property of of Enterprise Leader. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://theenterpriseleader.com/2018/04/02/kempharm-kmph-upgraded-at-valuengine.html.

KemPharm Company Profile

KemPharm, Inc, a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply